NCT05584007 RECRUITING Cellulitis Optimal Antibiotic Treatment
University of Southampton n=334
NCT07665476 NOT YET RECRUITING Naproxen Versus Placebo as Adjunct Treatment of Cellulitis: A Randomized Controlled Trial
Ottawa Hospital Research Institute n=884
NCT02814916 COMPLETED Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
AbbVie n=199
NCT02090764 COMPLETED Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
Ferrer Internacional S.A. n=412
NCT01252719 COMPLETED Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)
Melinta Therapeutics, Inc. n=968
NCT01252732 COMPLETED Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
Melinta Therapeutics, Inc. n=1,019
NCT04287777 COMPLETED Safety and Efficacy of Mupirocin Gel in Children With Impetigo
Reig Jofre Group n=467
NCT03556917 COMPLETED The Effects of Iontophoresis in Women With Gynoid Hidrolipodystrophy.
Universidade Norte do Paraná n=30
NCT02127970 COMPLETED Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Durata Therapeutics Inc., an affiliate of Allergan plc n=698
NCT00852540 COMPLETED Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
Stiefel, a GSK Company n=410
NCT00684177 COMPLETED Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)
GlaxoSmithKline n=508
NCT01397461 COMPLETED Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
Ferrer Internacional S.A. n=465
NCT02512614 COMPLETED Evaluation of Novel Antimicrobial Hand Towels
Centers for Disease Control and Prevention n=449
NCT01670032 COMPLETED Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo
NovaBay Pharmaceuticals, Inc. n=328
NCT01431339 COMPLETED Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Durata Therapeutics Inc., an affiliate of Allergan plc n=739
NCT01339091 COMPLETED Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Durata Therapeutics Inc., an affiliate of Allergan plc n=573
NCT01085929 COMPLETED Incision and Drainage Versus Needle Aspiration in Soft Tissue Abscesses
University of Massachusetts, Worcester n=101
